Seer to Spotlight Proteomics Strategy at Key Investor Conference

REDWOOD CITY, CA – February 18, 2026 – Seer, Inc. (Nasdaq: SEER), a company pioneering new frontiers in the study of proteins, is set to take the stage at the influential TD Cowen 46th Annual Health Care Conference in Boston. The company announced that its management will participate in a fireside chat on March 4, providing a crucial platform to communicate its strategic vision to investors and the broader healthcare industry just days after releasing its full-year financial results for 2025.

This appearance at one of the sector's premier events places Seer in a strategic spotlight. It offers an opportunity to detail the progress of its Proteograph Product Suite and articulate its long-term value proposition amid a challenging market environment and a rapidly evolving competitive landscape.

A Strategic Moment Under the Investor Microscope

The timing of the TD Cowen conference is particularly significant. Seer is scheduled to report its fourth-quarter and full-year 2025 financial results on February 26, meaning the fireside chat will be one of management's first opportunities to publicly contextualize that performance and provide an outlook for 2026. Investors will be listening closely for commentary on revenue trends, operating expenses, and the company's path forward.

Recent financial disclosures paint a mixed but intriguing picture. In the third quarter of 2025, Seer reported revenue of $4.1 million and an improved net loss of $18.2 million compared to the prior year. The company also maintained a robust cash position of approximately $251.2 million. However, it has faced market headwinds, with its stock underperforming the broader life sciences industry over the past year and holding a consensus "Sell" rating from analysts. Projections have indicated that profitability is not expected in the near term.

Despite these pressures, the company has shown confidence through action, having repurchased approximately $22 million of its shares under a $25 million program authorized in May 2024. The upcoming conference provides a forum for management to directly address investor concerns and reinforce its belief in the company’s intrinsic value and long-term growth trajectory, especially as it anticipates full-year 2025 revenue to land between $17 million and $18 million.

Beyond the Buzz: The Science of Deep Proteomics

At the heart of Seer's strategy is its groundbreaking technology, the Proteograph Product Suite. The company aims to solve a fundamental challenge in biology: achieving deep, unbiased, and large-scale insights into the proteome—the complete set of proteins expressed by an organism. Traditional methods have often struggled with the vast dynamic range of proteins in samples like blood plasma, where a few highly abundant proteins can mask thousands of others that may be critical biomarkers for disease.

Seer's key innovation lies in its proprietary engineered nanoparticles. These particles are designed to bind to proteins across their entire concentration range, allowing for the comprehensive analysis of both high- and low-abundance proteins in a single, automated workflow. This approach provides a more complete and unbiased picture of the proteome than conventional techniques, which often require complex and time-consuming depletion or enrichment steps that can introduce bias.

The integrated suite—combining these nanoparticles with the SP200 Automation Instrument, optimized consumables, and the Proteograph Analysis Suite software—is built for scale, speed, and reproducibility. Last year, at the ASMS 2025 conference, Seer launched its Proteograph ONE Assay, which significantly boosted scalability and reduced the per-sample analysis cost by approximately 60%. This enhancement enables researchers to process over 1,000 samples per week, making population-scale proteomic studies more feasible than ever before. While its products are designated for research use only and not for direct diagnostic procedures, their potential to accelerate biomarker discovery and translational research is immense.

Navigating the Crowded and Growing Proteomics Field

Seer is competing in a dynamic and rapidly expanding market. The global proteomics market was valued at over $31 billion in 2025 and is projected to surpass $100 billion by the early 2030s, fueled by surging investment in precision medicine, rising R&D spending by pharmaceutical companies, and the increasing integration of multi-omics data.

This lucrative space has attracted numerous players, from established giants like Thermo Fisher Scientific and Danaher Corporation to specialized proteomics firms such as Olink and SomaLogic. To carve out its niche, Seer is differentiating itself by focusing on providing unbiased depth at an unprecedented scale. While some competing technologies rely on antibody panels that target a predefined set of proteins, Seer's nanoparticle-based method is designed for discovery, capturing a broader, more impartial view of the proteome.

However, the path is not without obstacles. The industry faces challenges related to the high cost of instrumentation and the complexity of data analysis. Seer has also noted that uncertainties in government funding can impact spending from academic institutions, which represent a key customer segment. The fireside chat at TD Cowen will be an important moment for management to articulate how its strategy—particularly the cost-reduction and simplification offered by the Proteograph ONE platform—is positioned to overcome these hurdles and expand its market footprint.

Setting Expectations for the Fireside Chat

Attendees and webcast listeners will anticipate a discussion that moves beyond the press release, offering substantive insights into Seer’s operational and strategic direction. Key topics will likely include the market adoption and customer feedback for the Proteograph ONE platform, which is critical for driving future revenue growth.

Management is also expected to highlight recent scientific achievements that validate its technology. This includes a landmark study published in Nature Genetics in late 2025 that used the Proteograph platform to identify novel drug targets and biomarkers, as well as progress on major collaborations like the 20,000-sample cancer proteomics study with Korea University. These proof points are essential for building credibility within the scientific and investment communities.

Ultimately, the event represents a pivotal opportunity for Seer to connect the dots for investors: linking its advanced technology, recent financial performance, and strategic initiatives to a compelling vision for the future. The company will aim to demonstrate how its leadership in deep, unbiased proteomics is not just a scientific achievement but a cornerstone for future growth and a vital tool in advancing the next generation of biological research and precision medicine.